SG11202101779RA - Multi-chain chimeric polypeptides and uses thereof - Google Patents
Multi-chain chimeric polypeptides and uses thereofInfo
- Publication number
- SG11202101779RA SG11202101779RA SG11202101779RA SG11202101779RA SG11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA
- Authority
- SG
- Singapore
- Prior art keywords
- chimeric polypeptides
- chain chimeric
- chain
- polypeptides
- chimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725010P | 2018-08-30 | 2018-08-30 | |
US201862724969P | 2018-08-30 | 2018-08-30 | |
US201862725043P | 2018-08-30 | 2018-08-30 | |
US201862746832P | 2018-10-17 | 2018-10-17 | |
US201862749007P | 2018-10-22 | 2018-10-22 | |
US201862749506P | 2018-10-23 | 2018-10-23 | |
US201962816683P | 2019-03-11 | 2019-03-11 | |
US201962817230P | 2019-03-12 | 2019-03-12 | |
US201962817241P | 2019-03-12 | 2019-03-12 | |
US201962881088P | 2019-07-31 | 2019-07-31 | |
PCT/US2019/048881 WO2020047299A1 (en) | 2018-08-30 | 2019-08-29 | Multi-chain chimeric polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101779RA true SG11202101779RA (en) | 2021-03-30 |
Family
ID=67928938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101779RA SG11202101779RA (en) | 2018-08-30 | 2019-08-29 | Multi-chain chimeric polypeptides and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (7) | US11518792B2 (en) |
EP (1) | EP3844181A1 (en) |
JP (2) | JP7397874B2 (en) |
KR (1) | KR20210070287A (en) |
CN (1) | CN112996805A (en) |
AU (1) | AU2019328290A1 (en) |
CA (1) | CA3108949A1 (en) |
IL (1) | IL280918A (en) |
SG (1) | SG11202101779RA (en) |
TW (1) | TW202122416A (en) |
WO (1) | WO2020047299A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7397874B2 (en) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Multichain chimeric polypeptides and their uses |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP2022502088A (en) | 2018-09-27 | 2022-01-11 | エクシリオ デベロップメント, インコーポレイテッド | Masked cytokine polypeptide |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
IL295084A (en) * | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and uses thereof |
WO2021247003A1 (en) * | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
JP2023527869A (en) * | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Treatments for age-related disorders |
USD986799S1 (en) * | 2020-09-11 | 2023-05-23 | Wind Craft Aviation Inc. | Aircraft |
CN114042154A (en) * | 2021-12-14 | 2022-02-15 | 澳门大学 | Application of medicine composition in preparing anti-tumor combination therapy medicine |
WO2023134716A1 (en) * | 2022-01-14 | 2023-07-20 | 盛禾(中国)生物制药有限公司 | Bispecific antibody binding to b7h3 and nkp30, and application thereof |
WO2023168363A1 (en) * | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2023178333A1 (en) | 2022-03-18 | 2023-09-21 | WUGEN, Inc. | Improved chimeric receptor constructs for nk cells |
WO2023183853A1 (en) | 2022-03-22 | 2023-09-28 | WUGEN, Inc. | Hybrid promoters, vectors containing same and methods of use |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
HU220347B (en) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Composition for the specific coagulation of vasculature |
US6117980A (en) | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
JP2001206899A (en) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF |
US20010044427A1 (en) | 1999-12-20 | 2001-11-22 | Sidney Mazel | Pharmaceutical kit |
AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
DK1345969T3 (en) | 2000-12-26 | 2010-11-29 | Inst Nat Sante Rech Med | Anti-CD28 antibody |
US20040204481A1 (en) | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
AU2002355955A1 (en) | 2001-08-13 | 2003-03-03 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
TWI338009B (en) | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
WO2003104425A2 (en) | 2002-06-07 | 2003-12-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Novel stable anti-cd22 antibodies |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
BR0312692A (en) * | 2002-07-15 | 2007-06-26 | Univ Texas | selected antibodies and duramycin peptides that bind to anionic phospholipids and aminophospholipids and their uses in the treatment of viral infections and cancer |
CN1678744B (en) | 2002-08-30 | 2010-05-26 | 财团法人化学及血清疗法研究所 | Human antihuman interleukin-6 antibody and fragment of the antibody |
ES2559763T3 (en) | 2002-09-10 | 2016-02-15 | Affimed Gmbh | CD3 specific human antibody with immunosuppressive properties |
JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
WO2006113909A2 (en) | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
WO2004076488A1 (en) | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
KR20060015482A (en) | 2003-03-21 | 2006-02-17 | 와이어쓰 | Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
CA2525717A1 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP4939397B2 (en) | 2004-03-30 | 2012-05-23 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム | Bispecific antibodies for targeting cells involved in allergic reactions, and compositions and uses thereof |
US7393833B2 (en) * | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
BRPI0608096A2 (en) | 2005-04-26 | 2009-11-10 | Pfizer | p-cadherin antibodies |
ATE459648T1 (en) | 2005-05-11 | 2010-03-15 | Philogen Spa | FUSION PROTEIN OF ANTIBODIES L19 AGAINST FIBRONECTIN ED-B AND INTERLEUKIN 12 |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DK2274008T3 (en) | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Compositions and Methods for Inhibition of PDGFRBETA and VEGF-A |
CN110372792A (en) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | Inhibit the stabilization and soluble antibodies of VEGF |
RU2011104348A (en) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION |
WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
SI2376535T1 (en) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
KR20120060877A (en) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
DE102009045006A1 (en) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
NZ601580A (en) | 2010-02-11 | 2014-11-28 | Alexion Pharma Inc | Therapeutic methods using anti-cd200 antibodies |
EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
TR201807750T4 (en) | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antibody. |
KR20130100118A (en) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | Dual variable domain immunoglobulins and uses therof |
JP2012034668A (en) | 2010-08-12 | 2012-02-23 | Tohoku Univ | Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof |
PT2918607T (en) * | 2010-09-21 | 2018-01-11 | Altor Bioscience Corp | Multimeric il-15 soluble fusion molecules and methods of making and using same |
KR20130142128A (en) | 2010-10-11 | 2013-12-27 | 애브비 인코포레이티드 | Processes for purification of proteins |
CN102153653B (en) | 2010-12-30 | 2012-08-15 | 厦门大学 | Fusion protein of tumor blood vessel targeted polypeptide and tissue factor and preparation method thereof |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
KR101517320B1 (en) | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
RS57279B1 (en) | 2011-04-25 | 2018-08-31 | Daiichi Sankyo Co Ltd | Anti-b7-h3 antibody |
EP2714741B1 (en) | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
US9403911B2 (en) | 2011-06-06 | 2016-08-02 | Board Of Regents Of The University Of Nebraska | Compositions and methods for detection and treatment of cancer |
CN103747803B (en) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | Anti-AXL antibodies and application thereof |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
EP2776470A2 (en) | 2011-11-11 | 2014-09-17 | Rinat Neuroscience Corporation | Antibodies specific for trop-2 and their uses |
CN105861487B (en) | 2012-01-26 | 2020-05-05 | 纽亘技术公司 | Compositions and methods for targeted nucleic acid sequence enrichment and efficient library generation |
KR101535341B1 (en) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Novel monoclonal antibody that specifically binds to DLL4 and use thereof |
BR112015002085A2 (en) | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | protein, polynucleotide, vector, host cell, method for producing protein, pharmaceutical composition, protein use, method of treatment and invention |
WO2014026054A2 (en) | 2012-08-10 | 2014-02-13 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
CA2879494A1 (en) | 2012-08-28 | 2014-03-06 | Institut Curie | Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
ES2895848T3 (en) | 2012-12-17 | 2022-02-22 | Cell Medica Inc | Antibodies against IL-1 beta |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
US9790274B2 (en) | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
JP2015030666A (en) | 2013-07-31 | 2015-02-16 | 学校法人順天堂 | Anti-human cd26 monoclonal antibodies and antigen-binding fragments thereof |
CN103709251B (en) | 2013-12-19 | 2016-04-13 | 江苏众红生物工程创药研究院有限公司 | Total man source anti-CD 26 antibodies and application thereof |
KR102127408B1 (en) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | Anti-Her3 scFv fragment and Bispecific anti-c-Met/anti-Her3 antibodies comprising the same |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
FR3021970B1 (en) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES |
IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
WO2016030350A1 (en) | 2014-08-29 | 2016-03-03 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
CA2982657A1 (en) | 2015-04-17 | 2016-10-20 | Elsalys Biotech | Anti-tyro3 antibodies and uses thereof |
KR101778439B1 (en) | 2015-04-27 | 2017-09-14 | 울산대학교 산학협력단 | composition for improving immunity and anti-cancer activity comprising natural killer cell activator |
ES2841799T3 (en) | 2015-08-06 | 2021-07-09 | Agency Science Tech & Res | Antibodies to IL2R-Beta / common gamma chain |
JP6931228B2 (en) | 2015-09-11 | 2021-09-01 | ワイズ・エー・シー株式会社 | A composition for treating cancer in which an anti-CD26 antibody and another anti-cancer agent are combined. |
CR20220186A (en) | 2015-09-25 | 2022-07-07 | Genentech Inc | Anti-tigit antibodies and methods of use |
CN114853907A (en) | 2015-11-13 | 2022-08-05 | 达纳-法伯癌症研究所有限公司 | NKG2D-IG fusion protein for cancer immunotherapy |
WO2017149538A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
WO2017189526A1 (en) | 2016-04-25 | 2017-11-02 | Musc Foundation For Research Development | Activated cd26-high immune cells and cd26-negative immune cells and uses thereof |
US20180200366A1 (en) * | 2016-10-21 | 2018-07-19 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
EP3565846A4 (en) | 2017-01-03 | 2020-01-22 | Bioatla, LLC | Protein therapeutics for treatment of senescent cells |
EP3589316A1 (en) | 2017-02-28 | 2020-01-08 | Affimed GmbH | Combination of an anti-cd16a antibody with a cytokine |
KR102625293B1 (en) | 2017-03-06 | 2024-01-15 | 알토 바이오사이언스 엘엘씨 | IL-15-based fusion to IL-12 and IL-18 |
WO2018183169A1 (en) | 2017-03-27 | 2018-10-04 | Nantcell, Inc. | Ank and il-12 compositions and methods |
CA3074635A1 (en) | 2017-08-28 | 2019-03-07 | Altor Bioscience Llc | Il-15-based fusions to il-7 and il-21 |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
JP7397874B2 (en) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Multichain chimeric polypeptides and their uses |
US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
IL295083A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods of activating regulatory t cells |
IL295084A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and uses thereof |
IL295077A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods of treating age-related and inflammatory diseases |
US20220073578A1 (en) | 2020-06-01 | 2022-03-10 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
-
2019
- 2019-08-29 JP JP2021535496A patent/JP7397874B2/en active Active
- 2019-08-29 WO PCT/US2019/048881 patent/WO2020047299A1/en unknown
- 2019-08-29 CA CA3108949A patent/CA3108949A1/en active Pending
- 2019-08-29 AU AU2019328290A patent/AU2019328290A1/en active Pending
- 2019-08-29 CN CN201980070927.3A patent/CN112996805A/en active Pending
- 2019-08-29 EP EP19766444.4A patent/EP3844181A1/en active Pending
- 2019-08-29 SG SG11202101779RA patent/SG11202101779RA/en unknown
- 2019-08-29 US US16/555,689 patent/US11518792B2/en active Active
- 2019-08-29 KR KR1020217009434A patent/KR20210070287A/en unknown
- 2019-08-30 TW TW108131442A patent/TW202122416A/en unknown
-
2020
- 2020-11-19 US US16/952,861 patent/US11884712B2/en active Active
- 2020-11-19 US US16/952,848 patent/US20210070825A1/en active Pending
-
2021
- 2021-02-16 IL IL280918A patent/IL280918A/en unknown
-
2022
- 2022-10-19 US US18/047,754 patent/US20230272027A1/en active Pending
- 2022-10-19 US US18/047,751 patent/US20230128292A1/en active Pending
-
2023
- 2023-10-30 US US18/497,169 patent/US20240124544A1/en active Pending
- 2023-10-30 US US18/497,083 patent/US20240124543A1/en active Pending
- 2023-12-01 JP JP2023203880A patent/JP2024026248A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020047299A1 (en) | 2020-03-05 |
JP2021534828A (en) | 2021-12-16 |
TW202122416A (en) | 2021-06-16 |
JP7397874B2 (en) | 2023-12-13 |
US20230128292A1 (en) | 2023-04-27 |
AU2019328290A1 (en) | 2021-02-25 |
US20240124543A1 (en) | 2024-04-18 |
US20240124544A1 (en) | 2024-04-18 |
US20210070825A1 (en) | 2021-03-11 |
CA3108949A1 (en) | 2020-03-05 |
US11518792B2 (en) | 2022-12-06 |
EP3844181A1 (en) | 2021-07-07 |
JP2024026248A (en) | 2024-02-28 |
IL280918A (en) | 2021-04-29 |
KR20210070287A (en) | 2021-06-14 |
US20210070826A1 (en) | 2021-03-11 |
US20230272027A1 (en) | 2023-08-31 |
US11884712B2 (en) | 2024-01-30 |
US20200071374A1 (en) | 2020-03-05 |
CN112996805A (en) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280920A (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
IL280918A (en) | Multi-chain chimeric polypeptides and uses thereof | |
IL273327A (en) | Chimeric polypeptides and uses thereof | |
IL281776A (en) | Masked cytokine polypeptides | |
IL280915A (en) | Single-chain chimeric polypeptides and uses thereof | |
SG11202106257WA (en) | Chimeric receptor polypeptides and uses thereof | |
KR20220035394A (en) | Multi-chain chimeric polypeptides and uses thereof | |
IL287781A (en) | Clec12a-binding polypeptides and uses thereof | |
IL280808A (en) | Ox40-binding polypeptides and uses thereof | |
IL287782A (en) | Cd33-binding polypeptides and uses thereof | |
ZA201906235B (en) | Csf1r-based chimeric proteins | |
IL281088A (en) | Flt3l-based chimeric proteins | |
IL289122A (en) | Polypeptides | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
GB201707139D0 (en) | Polypeptides | |
IL289119A (en) | Polypeptides | |
IL281762A (en) | Arginase1 polypeptides | |
GB201719557D0 (en) | Polypeptide | |
IL268170A (en) | Vsig8-based chimeric proteins | |
EP3830105A4 (en) | Chimeric immunogenic polypeptides | |
GB201820556D0 (en) | Novel polypeptides | |
GB201810052D0 (en) | Polypeptide | |
GB201906126D0 (en) | Chimeric protein | |
GB201811755D0 (en) | Polypeptides | |
GB201807895D0 (en) | Polypeptides |